Pretax income is the income that a company earns before paying income taxes. Chiome Bioscience's pretax income for the
three
months ended in Dec. 2024 was 円0.0 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was 円-1,115.9 Mil.
Chiome Bioscience's pretax margin was %.
During the past 13 years, Chiome Bioscience's highest Pretax Margin was -130.32%. The lowest was -719.32%. And the median was -290.75%.
Chiome Bioscience Pre-Tax Income Historical Data
The historical data trend for Chiome Bioscience's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chiome Bioscience's Pre-Tax Income
For the Biotechnology subindustry, Chiome Bioscience's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,115.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) Pre-Tax Income Explanation
Chiome Bioscience's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Chiome Bioscience's highest Pretax Margin was -130.32%. The lowest was -719.32%. And the median was -290.75%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Chiome Bioscience's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4583 has been successfully added to your 